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Abstract 
Chemotherapy drugs usually inflict a lethal dose to tumour cells with the consequence that 
these cells are being killed by cell death. However, each round of chemotherapy also causes 
damage to normal somatic cells. The DNA cross-linking agent oxaliplatin which causes DNA 
double-strand breaks and vinflunine which disrupts the mitotic spindle are two of these 
chemotherapy drugs which were evaluated in vitro using peripheral lymphocytes from 
colorectal cancer patients and healthy individuals to determine any differential response. 
Endpoints examined included micronucleus (MN) induction using the cytokinesis-blocked 
micronucleus (CBMN) assay and pancentromeric fluorescence in situ hybridisation. Also, 
survivin expression was monitored since it regulates the mitotic spindle checkpoint and 
inhibits apoptosis. Oxaliplatin produced cytogenetic damage (MN in binucleated cells) via its 
clastogenic but also previously unknown aneugenic action, possibly through interfering with 
topoisomerase II, whilst vinflunine produced MN in mononucleated cells because of 
incomplete karyokinesis. Survivin expression was found to be significantly reduced in a 
concentration-dependent manner by not only oxaliplatin but surprisingly also vinflunine. This 
resulted in large numbers of multinucleated cells found with the CBMN assay. As survivin is 
upregulated in cancers, eliminating apoptosis inhibition might provide a more targeted 
chemotherapy approach; particularly, when considering vinflunine, which only affects cycling 
cells by inhibiting their mitotic spindle, and alongside possibly other pro-apoptotic 
compounds. Hence, these newly found properties vinflunine – the inhibition of survivin 
expression - might demonstrate a promising chemotherapeutic approach as vinflunine 
induces less DNA damage in normal somatic cells compared to other chemotherapeutic 
compounds. 
 
 
Alotaibi et al.   22-05-2017 
Page 3 of 30 
 
Keywords: Oxaliplatin, vinflunine, survivin, micronuclei assay, western blot 
  
Alotaibi et al.   22-05-2017 
Page 4 of 30 
 
1. Introduction 
Human peripheral blood lymphocytes (PBL) have been used for over half a century to 
monitor various genetic effects due to being exceptionally sensitive for in vivo and in vitro 
induced cytogenetic damage. This resulted in specific WHO guidelines for monitoring 
genotoxic effects of carcinogens in humans, in particular describing the use of PBL as 
surrogate cells and genotoxicity endpoints as predictors of human cancer risk (1). As PBL 
travel the entire circulatory system, with PBL sub-populations having mean lifespans of 6 
years (2), their individual and collective DNA integrity also reflects endogenously and 
exogenously induced damage from various stressors accumulated over time and distance. 
Hence, PBL originating from patients with cancer or with precancerous disease states have 
been shown to harbour an increased amount of cytogenetic damage while being increasingly 
more sensitive to DNA damaging agents than those from healthy individuals (3). The novel 
lymphocyte genome sensitivity assay for cancer diagnostics uses this differential PBL 
sensitivity to DNA a damaging stressor as a biomarker (4). Evaluating cytogenetic damage 
by detecting micronuclei (MN) in vitro in PBL cultures has been used for more than 20 years 
(5). In the cytokinesis-blocked MN (CBMN) assay, chromosomal acentric fragments from 
structural aberrations or even whole chromosomes can be recognized as extranuclear in the 
cytosol of cytokinesis-blocked binucleated cells (6) even linking these changes to cancer 
risks (7).  
A genotoxic drug may not only cause cytogenetic damage but also impair proteins involved 
in apoptosis and cell cycle control. Survivin, the smallest member of the inhibitor of apoptosis 
protein (IAP) family, is a highly conserved protein being implicated in inhibiting apoptosis by 
interfering with various caspases, but it also plays a regulatory role for the mitotic spindle 
checkpoint, the promotion of angiogenesis and chemoresistance (8,9). Several mitotic 
kinases, including the three Aurora kinases, Aurora-A, -B and -C, regulate the progression of 
the cell through mitosis. Evidence has shown that the proto-oncogene survivin acts as a 
mitotic regulator being expressed during mitosis in a cell cycle dependent manner. It 
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functions as a subunit of the chromosomal passenger complex, which is essential for proper 
chromosome segregation and cytokinesis. In this complex, Aurora B acts as the enzymatic 
core, while survivin dictates chromosomal passenger complex localization (10). X-ray 
crystallography has revealed an unusual bow tie-shaped dimer with two α-helical extensions 
interacting with the microtubules through these α-helical extensions at the carboxyl termini 
(11). Survivin is uniquely placed at the border of both the cell-death machinery and 
mechanisms of cell cycle progression / microtubule stability linking mitotic spindle functions 
to apoptotic pathways (12). Expressed in the G2/M phase, survivin is up-regulated in almost 
all cancers but has low or no expression in most normal, differentiated adult tissues (13). In 
colorectal cancer (CRC), survivin over-expression is stimulated by TCF/β-catenin, linking 
enhanced cell proliferation with resistance to apoptosis (14) and probably also to 
chromosomal instability (15). This promotes tumourigenesis but also cancer progression, 
poor prognosis, shortened patient survival and resistance to chemo- and radiation therapies 
(16).  
A number of molecules are able to modulate survivin expression and function in cancer cells 
through transcriptional mechanisms with an essential role for Sp1 sites and/or 
posttranscriptional mechanisms (17). The pro-apoptotic TP53 wild-type protein has been 
shown to effectively suppress survivin expression in normal cells by directly interacting with 
the TATA-less survivin promoter, while in cancer cells mutant TP53 contributes to over-
expression of survivin due to its inability to bind the promotor, acting in concert with 
increased anti-apoptotic phosphatidylinositol 3-kinase/Akt signalling (17,18). The increase in 
survivin expression has been found to be maintained throughout the different CRC stages, 
i.e. during the mucosa-adenoma-carcinoma sequence (19). At the protein level, 
phosphorylation of survivin is important for its biological activity; hence function and over-
expression strongly correlates with proliferative tumour activity indicating a possible role in 
cell cycle regulation and cancer progression (20). This makes IAP family members as a 
class of anti-apoptotic regulator proteins targets for novel therapeutic treatments (21,22). 
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Thus, survivin suppression can play a crucial role in such an approach, reversing 
suppression of apoptosis and increasing fidelity of chromosome segregation during mitosis. 
Oxaliplatin, a second generation diaminocyclohexane platinum complex, is an antineoplastic 
agent which induces apoptosis in CRC cells. The biological activity of oxaliplatin is mainly 
based on its ability to form lethal DNA lesions, including interstrand DNA crosslinks and 
DNA-protein crosslinks (23), leading to the induction of apoptosis by finally inducing double-
strand breaks as seen via persistent γ-H2AX foci (24). Oxaliplatin is also a potent inhibitor of 
survivin significantly reducing levels of protein in human CRC cell lines by p38 MAP kinase 
and the proteasome degradation pathway (25). However, the primary mechanism through 
which cell death occurs after exposure to oxaliplatin depends on the cell type and is not yet 
fully understood (26). Vinflunine on the other hand is a second generation Vinca alkaloid 
showing also anti-neoplastic activity in a wide spectrum of solid tumours. It acts by binding to 
tubulin and subsequently causes cells to arrest in mitosis (27). Vinflunine administration has 
been found to potentiate the anti-cancer activity of the platinum-based chemotherapeutic 
drug, cisplatin, in colon adenocarcinomas (28).  
The aim of this study was to investigate in vitro the cytogenetic effects of the cross-linking 
agent oxaliplatin and the spindle inhibitor vinflunine, both chemotherapeutic compounds, in 
PBL of healthy individuals and yet untreated colon cancer patients using the well-established 
and reliable cytokinesis-blocked micronucleus (CBMN) assay. In addition, survivin protein 
levels in PBL were assessed using Western blotting and were linked to the results from 
CBMN assay. 
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2. Methods 
If not stated otherwise all chemicals were generally purchased from Sigma-Aldrich, UK. 
2.1 Blood samples 
Ethical approval was granted for healthy non-smoking individuals by the University of 
Bradford Research Ethics sub-committee (reference no.: 0405/8) and for colorectal cancer 
patients by the Bradford Royal Infirmary Hospital local Ethics Committee (Reference no.: 
04Q1202/15). Peripheral blood was obtained after informed consent from 25 healthy non-
smoking volunteers and 25 colorectal cancer patients (prior to undergoing treatment). This 
limited the number of patients due to the small sampling window. 
2.2 CBMN assay 
The CBMN assay used is based on Fenech’s protocol (29). In brief, cultures were started 
with 500 µl of whole blood in RPMI 1640 with Glutamax-I supplemented with 15% foetal 
bovine serum, 1% penicillin-streptomycin solution) and 2.5% phytohaemagglutinin 
(chemicals from Invitrogen, UK) and incubated for 72 hours at 37 °C and 5% CO2. Treatment 
with oxaliplatin (0.02, 0.2 and 2 µM) and vinflunine (0.06, 0.6 and 6 µM; LGM Pharma, FL, 
USA) was carried out 24 hours into the culture. Mitomycin C (0.4 µM) was used for the 
positive control. Cell viability was measured using the Trypan blue exclusion viability test (1:2 
dilution with 0.4% Trypan blue; based on 100 evaluated cells) 1 hour after treatment. To 
exclude cytotoxic effects, any concentration producing cell viability below 75% was excluded 
(30). Cytokinesis was blocked using 6 µg/ml cytochalasin B after 44 hours. At the end of 
culture, cells treated with 110 mM KCl (15 min at 4 °C) and fixed with Carnoy’s solution (1 
part acetic acid and 3 parts methanol). For slide preparation, two drops (each 20 µl of the 
cell suspension) were dropped onto a clean glass slide and left to air-dry. Cells were stained 
using 5% filtered Giemsa (VWR, UK; in phosphate buffer, pH 6.8). Cover-slipped slides were 
used to evaluate the cells. The nuclear division index (NDI) based on 1,000 cells per 
concentration point was calculated according to the following formula: NDI = M1+ 2×M2+ 3×M3
𝑁
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(M1, M2 and M3 representing mononucleated, binucleated and multinucleated cells, 
respectively; N representing the total number of cells). The frequencies of induced MN were 
evaluated in 1,000 binucleated cells per concentration point. Frequencies of MN in 
mononucleated cells per concentration point were extrapolated to MN per 1,000 cells. Also, 
the frequencies of nucleoplasmic bridges (NPBs) and buds per 1,000 binucleated cells per 
concentration point were recorded. Statistical analysis was carried out using SPSS (version 
13). NDI data were analysed by the Chi-Square Test, while MN formation was analysed 
using the Fisher's Exact Test. 
2.3 Micronucleus fluorescence in situ hybridisation (MN-FISH) assay 
The MN-FISH assay was carried out using unstained MN assay slides as previously 
described (31). In brief, target DNA was denatured for 3 min at 75 °C in 70% formamide (in 
2x SSC, pH 7.0; Ambion) followed by dehydration in an ethanol series (70, 90 and 100%; 2 
min each) and allowed to air-dry. The hybridization mix containing 2 µl biotinylated pan-
centromeric DNA probe (32), 1 µl salmon sperm DNA (Invitrogen, UK) and 7 µl master mix 
(78.6% formamide, 14.3% dextran sulphate, 1.43x SSC, pH 7.0) was incubated for 10 min at 
75 °C to allow denaturation of the DNA probe. This hybridisation mix (10 µl per slide) was 
then applied onto air-dried slides followed by overnight incubation at 37 °C and washing in 
50% formamide (in 2x SSC, pH 7.0, 45 °C, 30 min) and in PN buffer (0.1 M Na2HPO4, 0.1 M 
Na H2PO4, 0.05% Igepal CA-640, pH 8.0, 45 °C, 10 min). Surfaces were blocked with PMN 
solution (5% non-fat dry milk powder in PN buffer, 0.1% NaN3, pH 8.0, 10 min) prior to 
applying 5 µg/ml fluorescein-conjugated avidin per slide (30 min at room temperature). 
Slides were washed for 10 min in PN buffer, DNA stained with 0.05 µg/ml 4',6-diamidino-2-
phenylindole (DAPI) and cover-slipped with antifade solution (0.2 M Trizma, pH 8.0, 90% 
glycerol, 2.33% 1,4-diazabicyclo[2.2.2]octane (DABCO)). A total of 100 binucleated cells 
containing MN were evaluated for the presence or the absence of pancentromeric signals 
(green fluorescence). For statistical analysis, the Fisher's Exact Test was used. 
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2.4 Western blot assay  
Cultures were set-up as described for the CBMN assay but using separated lymphocytes. 
For lymphocyte separation, two parts of diluted heparinised blood (1:2 with saline, 0.9% 
NaCl) were carefully layered on top of one part of Lymphoprep (Axis-shield, Norway) without 
disturbing the Lymphoprep layer. After centrifugation (650 xg; 20 min), the white PBL layer 
directly above the Lymphoprep layer was then transferred into 10 ml of saline. After a further 
centrifugation (400x g; 15 min) and removal of the supernatant, the pellet was resuspended 
in culture medium.  
Twenty-four hours after the start of the cultures, the medium was removed and cells were 
transferred into fresh medium; then treated with oxaliplatin (0.02, 0.2 and 2 µM) and 
vinflunine (0.06, 0.6 and 6 µM) prior to continuing the cultures for another 48 hours. Then 
cultures were centrifuged (500x g; 9 min) and pellets were washed twice in cold PBS) before 
being resuspended in RIPA buffer supplemented with protease inhibitor cocktail. After 30 
min on ice and a brief sonication (5 s, 30 W), the suspension was centrifuged (12,000x g, 30 
min) and the supernatant was collected. Total protein concentrations were then quantified by 
the method of Bradford (33). The polyacrylamide gel was prepared by overlaying the 
resolving gel (375 mM Trizma, pH 8.8, 0.1% SDS, 12% acrylamide/bis-acrylamide 19:1 (Bio-
Rad, UK), 0.05% ammonium persulfate, and 20 µl TEMED) with the stacking gel (125 mM 
Trizma, pH 6.8, 0.1% SDS, 4% acrylamide/bis-acrylamide 19:1, 0.05% ammonium persulfate 
and 5 µl TEMED). Protein samples were mixed (1:2) with 2x Laemmli buffer (4% SDS, 10% 
mercaptoethanol, 20% glycerol, 125 mM Trizma, pH 6.8, 0.004% bromophenol blue), boiled 
for 5 min, shortly spun and then loaded onto the gel. For each experiment a negative control 
with extracted protein from untreated cultures was used, while Jurkat whole cell lysate 
(Abcam, UK) served as a positive control. A biotinylated protein ladder (9-200 kDa; Cell 
Signalling, UK) was used as a size reference. The polyacrylamide gel was run as a 
discontinuous system employing a XCell SureLock mini cell (Invitrogen, UK) and 
electrophoresis buffer (25 mM Trizma, 192 mM glycine, 0.1% SDS). The voltage was set to 
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50 V for the passage through the stacking gel and to 100 V for 2 hours through the resolving 
gel. After the electrophoresis, proteins were transferred to a nitrocellulose blotting membrane 
using the iBlot® Gel Transfer Device (25 V, 9 min; Invitrogen, UK). The membrane was 
incubated for 1 hour at room temperature with blocking solution (5% bovine serum albumin 
in TBS-T buffer) and then washed 3x for 10 min with only TBS-T buffer (150 mM NaCl, 20 
mM Trizma, 0.1% Tween® 20, pH 7.4). Thereafter, the blotting membrane was incubated 
overnight at 4ºC on a shaker with the primary antibody (rabbit anti-Survivin monoclonal 
antibody ABfinity™ Recombinant (Invitrogen, UK); 1:2,000 in blocking solution). As an 
internal control the GAPDH rabbit monoclonal primary antibody (Invitrogen, UK) was used. 
Then, the secondary antibody (anti-rabbit IgG, horseradish peroxidase-linked antibody (Cell 
Signalling, UK); 1:3,000 in blocking solution) was added together with an HRP-conjugated 
anti-biotin antibody (Cell Signalling, UK; 1:1,000 in blocking solution) and incubation 
continued with gentle agitation for 1 hour before  washing the membrane 4x in TBS-T buffer 
for 15 min each. For staining, the enhanced chemiluminescence (ECL) kit solution 
(Amersham ECL Prime Western Blotting Detection Reagent; GE Healthcare Life Sciences, 
UK) was used before the membrane was exposed for 2 min to an Amersham Hyperfilm X ray 
film (GE Healthcare Life Sciences, UK). The film was then immediately developed (manual 
process using developer and fixer). Relative protein expression was determined by 
densitometric analysis using Scion Image (Scion Corporation, Fredrick, MD, USA). GAPDH 
served as the protein loading control. Statistical analysis was carried out using SPSS 
(version 13). Data from three independent experiments were assessed for normality using 
normal probability plots. The significance between treatment concentrations was analysed by 
One–way ANOVA followed by the Dunnett’s Post Hoc Test. 
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3. Results 
3.1 Nuclear division index (NDI) 
For determining the NDI, the frequencies of three different cell types were evaluated within a 
total number of 1,000 cells: mononucleated cells (MoNC), binucleated cells (BiNC) and 
multinucleated cells (MultiNC) containing three or four nuclei, respectively. It was shown that 
untreated PBL from healthy individuals and from CRC patients contained on average 26.1% 
and 25.5% MoNC, 72.8% and 70.8% BiNC as well as 1.1% and 3.7% MultiNC, respectively, 
resulting in NDI values of 1.73 and 1.82, respectively (Table 1).  
Oxaliplatin (2 µM) treatment significantly increased NDI values from 1.73 to 2.39 (p < 0.001) 
in PBL from healthy individuals and from 1.82 to 2.42 (p < 0.001) in those from CRC patients 
driven by a highly significant concentration-dependent increase in MultiNC from both donor 
groups (45.8-fold, p < 0.001, and 15.2-fold, p < 0.01, respectively) (Table 1). Even the 
smallest concentration of 0.02 µM yielded a significant increase in MultiNC (18.5-fold, p < 
0.001, and 7-fold, p < 0.05, respectively). At the same time the percentage of BiNC 
significantly decreased for the highest concentration by approximately one half (2.0-fold and 
2.4-fold, respectively; p < 0.01). Even for the lowest concentration the numbers of BiNC were 
reduced (1.2-fold and 1.5-fold, respectively) but not above significance; although, this trend 
towards lower numbers of BiNC was significantly stronger (p < 0.01) in PBL from CRC 
patients when compared to those from healthy individuals. Only the lower concentration of 
oxaliplatin (0.2 µM) significantly (p < 0.01) decreased the number of BiNC more in PBL from 
CRC patients when compared to those from healthy individuals. 
Vinflunine (0.6 µM) treatment significantly increased NDI values from 1.73 to 2.55 (p < 0.001) 
in PBL from healthy individuals and from 1.82 to 2.43 (p < 0.01) in those from CRC patients. 
Concomitantly, a highly significant concentration-dependent increase in MultiNC from both 
donor groups (52.0-fold, p < 0.001, and 15.4-fold, p < 0.01, respectively) was observed 
(Table 1). This increase in MultiNC was less prominent due to the 3.4-times higher baseline 
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frequency in PBL from CRC patients. The lower concentration of 0.06 µM also yielded a 
significant increase in MultiNC (15.1-fold, p < 0.01, and 6.1-fold, p < 0.05, respectively). Only 
at the higher concentration of 0.6 µM, the percentage of BiNC significantly decreased 1.7-
fold and 2.5-fold, respectively (p < 0.01) showing a significantly greater reduction (1.5-fold, p 
< 0.05) in PBL from CRC patients. Only the 0.6 µM concentration of vinflunine significantly (p 
< 0.05) decreased the number of BiNC more in PBL from CRC patients when compared to 
those from healthy individuals. 
3.2 Micronuclei induction 
The results for the MN formation are summarised in Table 1. The observed baseline damage 
in PBL from healthy individuals and from CRC patients was 3 MN and 10 MN per 1,000 
BiNC and 2 MN per 1,000 MoNC, respectively, indicating a trend towards higher cytogenetic 
damage in these PBL. Only the oxaliplatin treatment of PBL from healthy individuals and 
from CRC patients with concentrations of 0.02, 0.2 and 2 µM resulted in the formation of MN 
in BiNC at frequencies of 1.5% and 3.6% (both p < 0.01), 2.7% and 4.1% (both p < 0.001) as 
well as 3.7% and 5.3% (both p < 0.001), respectively. Vinflunine did not induce MN in BiNC. 
However, in contrast to oxaliplatin, vinflunine treatment at concentrations of 0.06 and 0.6 µM 
significantly induced the formation of MN in MoNC in PBL from both groups (observed 
baseline frequencies of 0.2% and 0.15%, respectively). Vinflunine significantly increased the 
number of MN in MoNC to 8.2% and 10.1% (p < 0.001) as well as to 12.5% and 12.9% (p < 
0.001), respectively, in PBL from healthy individuals and from CRC patients (Table 1). 
Furthermore, oxaliplatin treatment increased MN formation within MultiNC (data not shown), 
but such data were not taken into consideration (29).  
Besides MN, also nucleo-plasmatic bridges (NPBs) and buds were recorded. Frequencies in 
were very low (e.g. 2 NPBs in 100,000 BiNC). No significant increases regarding these two 
endpoints were found. Although, Table 1 shows that buds were more frequent in 
lymphocytes from patients from colon cancer patients. 
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3.3 Investigation of the origin of MN formation by MN-FISH 
Using the MN-FISH assay the mechanism of oxaliplatin-induced MN formation was 
investigated in order to differentiate between clastogenicity (acentric DNA fragments) and 
aneuploidy (missegregated chromosomes with a centromere) (29). For each of the 
oxaliplatin concentrations 0.02, 0.2 and 2 µM and for each of the two groups (healthy 
individuals and CRC patients) hundred aberrant BiNC that carry MN were evaluated (Figure 
1). With increasing concentrations and for both groups ~60%, ~70% and ~80% of the MN 
were centromere-positive (C+MN). The results for PBL from healthy individuals or CRC 
patients, respectively, were all significantly different (p < 0.001) from the negative controls. 
The latter only showed levels below 10% for both groups and the majority of MN found in 
BiNC to be centromere-negative, thus, chromosomal fragments. Also, MN in MultiNC after 
treatment with oxaliplatin resulted from missegregated chromosomes as indicated by mainly 
centromere-positive MN (data not shown).  
3.4 Inhibition of survivin expression by oxaliplatin and vinflunine in PBL from colon 
cancer patients 
The survivin protein expression in PBL from colon cancer patients treated with 0.02, 0.2 and 
2 μM oxaliplatin was evaluated. Untreated cells were used as a negative control to determine 
the cut-off value of survivin overexpression for comparison. For all tested oxaliplatin 
concentrations the expression of survivin was significantly reduced (Figure 2a). Survivin 
expression in PBL from colon cancer patients following treatment with different 
concentrations of oxaliplatin. The control consisted of untreated PBL and the significant 
differences were shown in relation to the control (Figure 2b). Lane 1 represents survivin 
expression in untreated PBL from colorectal cancer patients (negative control) while lane 2 
represents survivin expression in Jurkat cells (positive control). Lanes 3-5 represent the 
survivin expression in treated PBL using 0.02, 0.2 and 2 μM oxaliplatin, respectively. 
Constitutively expressed GAPDH was used as loading control. The data presented result 
from three independent experiments using three male colon cancer patients (n = 3). 
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The reduction was concentration dependent. When normalised to the control levels, survivin 
expression in oxaliplatin-treated PBL was reduced by 10% (1.3-fold decrease, p < 0.05) at a 
concentration of 0.02 μM, by 39% at a concentration of 0.2 μM (1.6-fold decrease, p < 0.01) 
and by 72% (3.6-fold decrease, p < 0.01) at the highest concentration of 2 μM (Figure 2a).  
Vinflunine only produced at the higher concentrations of 0.6 and 6 μM a statistically 
significant reduction in survivin expression by 39% (1.6-fold decrease, p < 0.01) and by 85% 
(6.7-fold decrease, p < 0.01), respectively (Figures 3a and 3b). There was no statistically 
significant difference between the survivin expression levels of untreated and 0.06 μM 
vinflunine-treated PBL.  
4. Discussion 
It has been known that lymphocytes originating from cancer patients show a higher 
frequency of cytogenetic damage. They are also more sensitive to DNA damaging, genotoxic 
agents than PBL from healthy individuals allowing an explicit comparison between these 
different donor groups (3). Hence, this study uses PBL from healthy individuals and CRC 
patients to investigate two chemotherapeutic compounds, oxaliplatin and vinflunine. While 
the NDI, the percentages of MoNC and BiNC were found to be in the same range (Table 1), 
the percentage of MulitNC showed a trend to be higher in PBL from CRC patients. Also, the 
baseline MN frequency per 1,000 BiNC was slightly increased in PBL from healthy 
individuals compared to those of CRC patients. This increase, even though not significant, 
showed a trend towards higher cytogenetic damage in PBL from CRC patients as previously 
shown for MN induction or for genotoxic damage in the Comet assay (4). 
Both investigated compounds follow two different modes of DNA damaging action: oxaliplatin 
acts via inducing significant mitochondrial oxidative stress (34) and DNA cross-links (35); 
thus, if not repaired correctly, the induction of DNA double-strand breaks, while vinflunine 
disturbs and inhibits the spindle apparatus (36) leading to missegregated chromosomes. As 
a consequence, oxaliplatin mainly creates structural aberrations whereas vinflunine mainly 
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induces numerical abnormalities. Our findings (Table 1) showed that with increasing 
concentrations of oxaliplatin (0.02, 0.2 and 2 µM) the induction of MN in PBL from healthy 
individuals and CRC patients significantly increased in vitro for all three concentrations 
(Table 1). At the highest concentration, this increase was 12.4-fold in PBL from healthy 
individuals and 5.3-fold in PBL from CRC patients (both, p < 0.001) being in the range of the  
positive control (0.4 µM mitomycin C). The higher fold-increase of MN in PBL from healthy 
individuals was due to the lower baseline damage in untreated PBL compared to PBL from 
CRC patients. The actual number of induced MN in PBL of the latter group was 1.4-times 
higher confirming earlier findings that PBL from cancer patients are showing higher baseline 
damage and greater sensitivity(3). 
In contrast, both evaluated concentrations of vinflunine (0.06 and 0.6 µM) did not show any 
increase in micronuclei above baseline frequencies. This clearly demonstrates the expected 
clastogenic action of oxaliplatin and that PBL from CRC patients are indeed more sensitive 
to cytogenetic damage caused by the action of oxaliplatin. Such micronuclei may either 
contain acentric chromosomal fragments or missegregated whole chromosomes that are 
defined by their centromeres (29); hence, using pan-centromeric fluorescence in situ 
hybridisation probes (31), the percentages of centromere-positive MN (C+MN) in BiNC were 
assessed in PBL of both donor groups (Figure 1) showing a highly significant (p< 0.001) 
concentration-dependent increase in C+MN to percentages of 56%, 78% and 82%, 
respectively, for the three oxaliplatin concentrations. There is also a tendency to even higher 
frequencies of C+MN when treating PBL from CRC patients with oxaliplatin (Figure 1). This 
result clearly demonstrates that oxaliplatin not only acts as a the well-known clastogenic 
compound (37), but unexpectedly also as an aneugen leading to missegregated whole 
chromosomes. So far, only cisplatin has been found to cause dose-dependent 
endoreduplication in Chinese hamster cells; hence, producing chromosome instability and 
polyploidy (38).  
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The frequencies of MN found in MoNC (Table 1) stayed for all three concentrations of 
oxaliplatin and the positive control at negative control levels. For vinflunine on the other 
hand, an extremely large, highly significant (p < 0.001) number of MN was observed in 
MoNC in PBL from healthy individuals (53.6 and 81.7-fold increase) and from CRC patients 
(50.5 and 64.5-fold) for both evaluated non-cytotoxic concentrations, evidently indicating that 
this compound acted in disrupting the spindle and inhibiting karyokinesis; thus, also 
impeding cytokinesis which resulted in a significantly increased number of MoNC and MN 
within them. This shows that the mechanism in which vinblastine causes aneuploidy is 
different from the novel aneugenic action found for oxaliplatin. Hence, oxaliplatin does not 
target the spindle apparatus like vinflunine but more likely interferes with DNA 
topoisomerase II and enzyme essential for segregating replicated chromosomes during 
mitosis (38,39). These different modes of action for both chemicals can also be observed by 
calculating the nuclear division index (NDI) using the numbers of MoNC, BiNC and MultiNC 
per concentration point (29); however, for oxaliplatin and vinflunine, this lead to unexpected 
results. All three oxaliplatin concentrations significantly increased the NDI in PBL from both 
donor groups (Table 1). The same was seen to an equal extent for vinflunine, except for the 
lower concentration in PBL from healthy individuals where the result did not reach 
significance. For both compounds, a NDI decrease would have been expected due to cell 
cycle inhibition caused by the induction of DNA damage (35) or spindle disruption (40). But it 
was indeed found that the NDI increases – driven by a significant 15-fold increase in the 
number of multinucleated cells (for percentages see Table 1) for the high concentrations of 
oxaliplatin and vinflunine. Usually, the occurrence of large numbers of MultiNC in the CBMN 
assay indicates an increased cell cycle rate. Hence, it was rather confusing at first why such 
an effect was observed as both compounds would normally induce cell cycle arrest due to 
the introduction of either DNA lesions (41) or the disruption of spindle microtubules (40). 
Interestingly, another platinum-based chemotherapeutic compound, satraplatin (42), did not 
show an increase in MultiNC using the same assay (data not shown). 
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Anti-tumour drugs can lead to a form of cell death in treated cells called mitotic catastrophe. 
Kondo proposed in 1995 a concept of a 'G1/G2 death circuit' where cells dying in the gap 
phases of the cell cycle might short circuit to M phase (43). Mitotic catastrophe is generally 
characterized by an aberrant mitosis and the formation of large cells containing multiple 
nuclei (44); hence, the increased frequency of multinucleated cells by oxaliplatin and 
vinflunine found in this study. At the molecular level, the unusual high number of induced 
multinucleated cells by oxaliplatin and vinflunine can be explained by the decreased 
expression of the anti-apoptotic protein survivin after in vitro treatment. Survivin belongs to 
the IAP family inhibiting apoptosis and promoting cell growth by microtubule stabilisation 
during mitosis (45). Survivin also interacts with other proteins such as aurora B in the cell 
functioning as a spindle checkpoint, regulating chromosome segregation and maintaining 
genomic stability (46). It has been demonstrated that a lack of survivin results in a disrupted 
cell division, mitotic catastrophe and subsequently in polyploidy (47). Survivin seems to be a 
key target of oxaliplatin (48) and expression of survivin was found to be significantly reduced 
for all three oxaliplatin concentrations (Figure 2a). When treating PBL with vinflunine a 
significant reduction of survivin expression was also observed but only for the concentrations 
0.6 and 6 µM (Figure 3a). Although, the highest concentration of 6 µM vinflunine was 
cytotoxic in the MN assay when using established treatment times. It has been previously 
shown that survivin is upregulated in many cancers (49) where it is targeted as a molecular 
biomarker (50). The chemotherapeutic drug oxaliplatin was found to down-regulate survivin 
in colon cancer cells via p38 MAP kinase and proteasome degradation pathways (25) and 
aids to reduce resistance to chemotherapy (51). Inhibiting survivin significantly decreased 
tumour growth and induced apoptosis, hence it became an attractive target for CRC 
treatment (52) as over-expression of survivin together with down-regulated tumour 
suppressor miR-16-1 in CRC stem cells (CCSC) is thought to be one of the primary causes 
for therapy failure. Therefore, the search for new anti-proliferative agents which target 
survivin or miR-16-1 in CCSC is warranted. Prodigiosin, a compound isolated from the cell 
wall of Serratia marcescens, has been shown to strongly induce apoptosis in various cancer 
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cells by targeting survivin and miRNA-16-1, which makes it a potential candidate for a direct  
therapeutic approach against CCSC (53). 
Our study confirmed oxaliplatin’s and vinflunine’s DNA damaging action on PBL from healthy 
individuals and CRC patients. For the first time, it has been shown that oxaliplatin also acts 
as an aneugen causing missegregation of chromosomes possibly by interfering with 
topoisomerase II as well as inhibiting survivin expression. Vinflunine on the other hand is a 
spindle inhibitor and thus a drug specifically acting only on cycling cells also inhibits survivin 
expression. Targeting the mitotic regulator and inhibitor of apoptosis survivin significantly 
inhibited its gene expression. As a consequence, a surge of multinucleated cells can be 
seen in the CBMN assay for both chemicals for both donor groups. PBL from cancer patients 
show higher frequencies due to their higher sensitivity when compared to those from healthy 
individuals; hence, both compounds are able to induce significant cytogenetic damage, 
oxaliplatin via inducing general DNA damage and vinflunine via only inhibiting specifically 
cycling cells. Oxaliplatin but also vinflunine significantly reduces the cells’ anti-apoptotic 
potential by inhibiting survivin expression while causing cell cycle shortcuts. Future 
chemotherapeutic approaches using a smart mix of different concentrations of oxaliplatin 
and vinflunine might then be able to reduce harm to all somatic cells by only targeting cycling 
cancer cells.  
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Table legend 
Table 1: The effects of oxaliplatin (OXP) and vinflunine (VFN) evaluated by the CBMN assay 
using PBL from healthy individuals and colorectal cancer patients. MoNC represent 
mononucleated cells, BiNC binucleated cells and MultiNC multinucleated cells. The highest 
vinflunine dose (6 μM) was cytotoxic. Data represent mean values. The results were 
normally distributed; therefore, the data were analysed by one-way ANOVA followed by 
Dunnett’s post hoc test for significant differences compared to untreated PBL (* p < 0.01, ** p 
< 0.01, *** p < 0.001). Significant differences of the impact of the compounds in PBL from 
healthy individuals and colorectal cancer patients were analysed by chi-square (χ2) test (+ p 
< 0.05, ++ p < 0.01, +++ p < 0.001; n = 25). 
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Figure legends 
 
Figure 1: Fluorescence in situ hybridization (FISH) of oxaliplatin induced MN in binucleated 
cells. The figure shows the percentage of micronuclei originated from a whole chromosome 
as indicated by positive pancentromeric probe signal (C+MN) after treatment with oxaliplatin. 
Data were analysed with a Fisher's Exact Test for statically differences (*** p < 0.001; n = 
25). 
Figure 2a: Survivin expression in PBL from colon cancer patients following treatment with 
different concentrations of oxaliplatin. The control consisted of untreated PBL. Significant 
differences in relation to the control (* p < 0.05, ** p < 0.01). The data presented result from 
three independent experiments using three male colon cancer patients (n = 3). 
Figure 2b: Western blot of survivin expression in PBL from colon cancer patients following 
treatment with different concentrations of oxaliplatin. Lane 1: survivin expression in untreated 
PBL from colorectal cancer patients (negative control); lane 2: survivin expression in Jurkat 
cells (positive control); lanes 3-5: survivin expression in treated PBL using 0.02, 0.2 and 2 
μM oxaliplatin, respectively. Constitutively expressed GAPDH was used as loading control. 
Figure 3a: Survivin expression in PBL from colon cancer patients after treatment with 
different concentrations of vinflunine. The control consisted of untreated PBL. Significant 
differences in relation to the control (** p < 0.01). The data presented result of three 
independent experiments using three male colon cancer patients (n = 3). 
Figure 3b: Western blot of survivin expression in PBL from colon cancer patients after 
treatment with different concentrations of vinflunine. Lane 1: survivin expression in untreated 
PBL from colorectal cancer patients (negative control); lanes 2-4: survivin expression in 
treated PBL using 0.06, 0.6 and 6 μM vinflunine. Constitutively expressed GAPDH was used 
as loading control. 
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Table 1 
 
 Lymphocyte treatment 
BiNC 
(%) 
MultiNC 
(%) NDI 
MN NPBs Buds MN  
in 1,000 
MoNC in 1,000 BiNC 
Healthy 
Individuals Control 72.8 1.09 1.73 3 0.02 0.0 1.53 
 0.4 µM MMC 61.13 1.51 1.61 51 3.15 0.24 2.04 
 0.02 µM OXP 60.03 20.2*** 2.13* 14.62** 0.05 0.0 1.06 
 0.2 µM OXP 38.4** 49.3*** 2.37** 26.88*** 0.04 0.0 2.04 
 2 µM OXP 36.9** 49.9*** 2.39*** 37.14*** 0.08 0.0 3.11 
 0.06 µM VFN 60.03 16.5** 1.92 4 0.73 0.3 82*** 
 0.6 µM VFN 41.8** 56.6*** 2.55*** 3 1.02 0.5 125*** 
 6 µM VFN - - - - - - - 
CRC 
patients Control 70.8 3.7 1.82 10 0.02 0.34 2 
 0.4 µM MMC 61.13 2.8 1.66 59.33 0.05 1.07 2.52 
 0.02 µM OXP 47.4++ 26.03* 2.01** 36** 0.12 0.52 3.10 
 0.2 µM OXP 31.2** 53.1** 2.39*** 41*** 0.30 0.83 3.79 
 2 µM OXP 29.7** 56.4** 2.42*** 53*** 0.22 0.95 4 
 0.06 µM VFN 57.1 22.5* 2.14* 13 0.07 0.0 101*** 
 0.6 µM VFN 28.9** + 57.1** 2.43** 10 0.09 0.33 129*** 
 6 µM VFN - - - - - - - 
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Figure 1 
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Figure 2a 
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Figure 2b 
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Figure 3a 
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Figure 3b 
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